BRAIN Biotech AG (HAM:BNN) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


HAM:BNN BRAIN Biotech AG HAM:BNN
65 GF Score
Price €2.82
GF Value €2.52
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BRAIN Biotech AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

HAM:BNN vs LIN, SHW, ECL: Margin of Safety % (DCF FCF Based) Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG Margin of Safety % (DCF FCF Based) vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Margin of Safety % (DCF FCF Based) falls into.


HAM:BNN
65GF Score
BRAIN Biotech AG HAM:BNN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.82 is trading 11.9% above its estimated GF Value™ of €2.52. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €2.52 vs. price of €2.82 (11.9% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score

Get the complete analysis for HAM:BNN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.82
Price
€2.52
GF Value